An interventional study of Camel Snus and Marlboro Snus in Tobacco Use Disorder, sponsored by University of Minnesota. Completed at 2 sites in United States. Open to participants aged 18 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-11-18.
Sponsored by University of Minnesota · Not applicable, Interventional, and Treatment
Recently, tobacco companies have developed new oral tobacco products that are purportedly less harmful than conventional tobacco products. These products have not been tested by independent research for their health effects or consumer palatability. In addition, it is not known if these products will be used in addition to cigarette smoking or as a substitute to cigarettes. These two studies will examine four oral tobacco products to answer some of these questions.
The goals of this first study will be to examine: 1) the brand of oral tobacco products which is preferred by cigarette smokers and the pattern and amount of product use when used as a switching tool; 2) the characteristics that are associated with product choice; 3) nicotine exposure from these products; and 4) the withdrawal symptoms from the tobacco products and potential for continued use.
Specifically, our primary aims hypotheses were: 1) the product that will be chosen by most smokers will be based on taste and sensory aspects of the product with products higher in nicotine content more likely to be chosen as the preferred product; and 2) subjects will experience no difficulty using the product for complete cigarette substitution, but a small minority will engage in dual product use.
For the secondary aims, we hypothesized: 1) that compared to the subjects' own brand of cigarettes, the biomarkers for exposure for the oral tobacco products will be significantly lower; 2) withdrawal symptoms from the oral products are likely to occur, but are likely to be mild compared to cigarette withdrawal.
This study will be accomplished by allowing subjects to sample the products and choose one oral tobacco product that they will use instead of cigarettes for a two week period. After the two weeks, they will discontinue all tobacco use and withdrawal symptoms and abstinence rates will be observed.
Subjects will attend an orientation visit where the study will be explained in detail. Interested subjects will sign a consent form and be scheduled to return for baseline measures. Subjects will have a review of medical history to verify that they are in generally good health and do not have contraindications to the study products. Eligible subjects will collect one week of baseline measures while smoking at their normal rate: measures include daily diaries of smoking, questionnaires and urine samples. At the second baseline visit, they will receive samples of the oral tobacco products. The tobacco products tested are five novel oral products recently introduced to the market: 1) Camel Snus (higher nicotine); 2) General Snus (higher nicotine); 3) Marlboro Snus (lower nicotine); and two compressed tobacco tablets, 4) Ariva (lower nicotine), or 5) Stonewall (higher nicotine). All of these tobacco products are purported to have reduced levels of tobacco-specific nitrosamines.
During sample weeks, subjects will be given 10 pouches/tablets of each product in a within-subject design and instructed to use at least three of the daily products in the morning of sample day and resume smoking in the afternoon and through the following day. They will sample the next product in a similar manner. The order of product was randomized. All subjects will sample all five products. This design will allow a short, but adequate trial of each product to determine preference. After the sampling weeks, subjects will choose the product they will want to use to quit smoking. They will be supplied that product over the next two weeks.
During the two weeks of product use during smoking abstinence, subjects will come to weekly clinic visits and then a follow-up visits at 1 week and a phone call at 4 weeks after the end of treatment. At baseline, and 2 weeks post cigarette cessation, subjects will bring in a urine sample from their first morning void and bloods will be drawn. At each visit, subjects will have vital signs obtained (blood pressure, heart rate, weight and carbon monoxide level), they will complete several subjective forms regarding tobacco use, withdrawal symptoms, and mood. Subjects will receive brief behavioral counseling for smoking cessation at all visits.
In addition, during the sample weeks and at the end of two weeks of study product use, subjects will submit three used chews that will be sent to CDC to be analyzed for the tobacco constituents.
968 studies on the registry are indexed under Tobacco Use Disorder; 127 are open to participants now.
This study's enrollment of 104 is above the median of 90 across 851 interventional studies indexed under Tobacco Use Disorder.
Browse Tobacco Use Disorder studies →University of Minnesota is the lead sponsor of 1,185 studies on the registry; 196 are open to participants now.
Of its 132 completed or terminated interventional studies of FDA-regulated products, 92 (70%) have results posted.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Camel Snus (oral smokeless tobacco product). Dosage: 1.74-1.97 mg nicotine per portion.
Other: Camel Snus
Marlboro Snus (oral smokeless tobacco product). Dosage: 0.14 - 0.38 mg nicotine per portion.
Other: Marlboro Snus
Stonewall (oral dissolvable tobacco product). Dosage: 0.28-0.57 mg nicotine per portion.
Other: Stonewall
Ariva (oral dissolvable tobacco product). Dosage: 0.24-0.25 mg nicotine per portion.
Other: Ariva
General Snus (oral smokeless tobacco product); Dosage: 3.37 mg nicotine.
Other: General Snus
All subjects will sample Camel Snus and determine if they would prefer to use this product during the abstinence phase over the other products sampled. Sampling period (duration: 1/2 day) requires use of at least 3 samples of Camel Snus. Intervention period (duration: 2 weeks) involves ad libitum daily use (if Camel Snus is chosen for use) during abstinence phase.
All subjects will sample Marlboro Snus and determine if they would prefer to use this product during the abstinence phase over the other products sampled. Sampling period (duration: 1/2 day) requires use of at least 3 samples of Marlboro Snus. Intervention period (duration: 2 weeks) involves ad libitum daily use (if Marlboro Snus is chosen for use) during abstinence phase.
All subjects will sample Stonewall and determine if they would prefer to use this product during the abstinence phase over the other products sampled. Sampling period (duration: 1/2 day) requires use of at least 3 samples of Stonewall. Intervention period (duration: 2 weeks) involves ad libitum daily use (if Stonewall is chosen for use) during abstinence phase.
All subjects will sample Ariva and determine if they would prefer to use this product during the abstinence phase over the other products sampled. Sampling period (duration: 1/2 day) requires use of at least 3 samples of Ariva. Intervention period (duration: 2 weeks) involves ad libitum daily use (if Ariva is chosen for use) during abstinence phase.
All subjects will sample General Snus and determine if they would prefer to use this product during the abstinence phase over the other products sampled. Sampling period (duration: 1/2 day) requires use of at least 3 samples of General Snus. Intervention period (duration: 2 weeks) involves ad libitum daily use (if General Snus is chosen for use) during abstinence phase.
Product Preference
Number of individuals who selected each of the products (e.g., Camel Snus, Marlboro Snus, General Snus, Ariva, Stonewall).
Time frame: 2 weeks
Abstinence From Cigarettes
Abstinence from cigarettes during Abstinence Phase.
Time frame: Survival (abstinence) at 3 weeks (2 weeks intervention and 1 week follow-up)
Subjects were recruited 10/2008 through 8/2009 through local advertisements in Minnesota and Oregon.
| Milestone | Oral Tobacco Products |
|---|---|
| Started | 104 |
| Completed | 91 |
| Not completed | 13 |
| Withdrew: Lack of efficacy | 5 |
| Withdrew: Withdrawal by subject | 8 |
Number of individuals who selected each of the products (e.g., Camel Snus, Marlboro Snus, General Snus, Ariva, Stonewall).
| participants | Camel Snus | Marlboro Snus | Stonewall | Ariva | General Snus |
|---|---|---|---|---|---|
| Product Preference | 27 | 23 | 24 | 24 | 0 |
Abstinence from cigarettes during Abstinence Phase.
| Participants | Camel Snus | Marlboro Snus | Stonewall | Ariva |
|---|---|---|---|---|
| Abstinence From Cigarettes | 12 | 8 | 5 | 3 |
Collected over 3 weeks. Non-serious events are listed at a 3% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Camel Snus | — | 0/98 (0%) | 9/98 (9.2%) |
| Marlboro Snus | — | 0/98 (0%) | 5/98 (5.1%) |
| Stonewall | — | 0/98 (0%) | 9/98 (9.2%) |
| Ariva | — | 0/98 (0%) | 5/98 (5.1%) |
| General Snus | — | 0/98 (0%) | 23/98 (23.5%) |
| Event | Camel Snus | Marlboro Snus | Stonewall | Ariva | General Snus |
|---|---|---|---|---|---|
| Excessive SalivationGeneral disorders | 6/98 | 2/98 | 1/98 | 2/98 | 14/98 |
| Sore ThroatGeneral disorders | 2/98 | 1/98 | 2/98 | 1/98 | 6/98 |
| Dry MouthGeneral disorders | 1/98 | 2/98 | 3/98 | 1/98 | 0/98 |
| Dizziness/LightheadednessGeneral disorders | 0/98 | 0/98 | 3/98 | 1/98 | 3/98 |
| Age, Categorical(Participants) | Oral Tobacco Products |
|---|---|
| <=18 years | 2 |
| Between 18 and 65 years | 97 |
| >=65 years | 5 |
| Age, Continuous(years) | Oral Tobacco Products |
|---|---|
| Mean | 40.1 ± 13.2 |
| Sex: Female, Male(Participants) | Oral Tobacco Products |
|---|---|
| Female | 40 |
| Male | 64 |
| Region of Enrollment(participants) | Oral Tobacco Products |
|---|---|
| United States | 104 |
Plan to share: No
No publications or documents are linked to this record.
This study is completed, as verified in Oct 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of Minnesota